Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Jul;142(6):1015-9.
doi: 10.1038/sj.bjp.0705868. Epub 2004 Jun 21.

Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor

Affiliations
Comparative Study

Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor

Anne N Shemon et al. Br J Pharmacol. 2004 Jul.

Abstract

1 Extracellular ATP can activate a cation-selective channel/pore on human B-lymphocytes, known as the P2X7 receptor. Activation of this receptor is linked to PLD stimulation. We have used ATP-induced 86Rb+ (K+) efflux to examine the effect of benzophenanthridine alkaloids on P2X7 channel/pore function in human B-lymphocytes. 2 Both ATP and the nucleotide analogue 2'-3'-O-(4-benzoylbenzoyl)-ATP (BzATP) induced an 86Rb+ efflux, which was completely inhibited by the isoquinoline derivative 1-(N,O-bis[5-isoquinolinesulphonyl]-N-methyl-l-tyrosyl)-4-phenylpiperazine (KN-62), a potent P2X7 receptor antagonist. 3 The benzophenanthridine alkaloid chelerythrine, a potent PKC inhibitor, inhibited the ATP-induced 86Rb+ efflux by 73.4+/-3.5% and with an IC50 of 5.6+/-2.3 microm. Similarly, other members of this family of compounds, sanguinarine and berberine, blocked the ATP-induced 86Rb+ efflux by 58.8+/-4.8 and 61.1+/-8.0%, respectively. 4 Concentration-effect curves to ATP estimated an EC50 value of 78 microm and in the presence of 5 and 10 microm chelerythrine this increased slightly to 110 and 150 microm, respectively, which fits a noncompetitive inhibitor profile for chelerythrine. 5 Chelerythrine at 10 microm was effective at inhibiting the ATP-induced PLD stimulation in B-lymphocytes by 94.2+/-21.9% and the phorbol 12-myristate 13-acetate-induced PLD stimulation by 68.2+/-7.4%. 6 This study demonstrates that chelerythrine in addition to PKC inhibition has a noncompetitive inhibitory action on the P2X7 receptor itself.

PubMed Disclaimer

Figures

Figure 1
Figure 1
P2X7 activation mediates 86Rb+ efflux from human B-lymphocytes. 86Rb+-loaded CLL B-lymphocytes in KCl (for ATP) or NaCl (for BzATP) medium supplemented with 20 μM CaCl2 were pre-incubated at 37°C for 5 min in the absence or presence of 1 μM KN-62, before the addition of 100 μM ATP or 20 μM BzATP for a further 4 min. The data are one representative of nine experiments for ATP and one representative of two experiments for BzATP and KN-62.
Figure 2
Figure 2
Chelerythrine and its structural analogues, sanguinarine and berberine, block ATP-induced 86Rb+ efflux. 86Rb+-loaded CLL B-lymphocytes in KCl medium containing 20 μM CaCl2 were pre-incubated for 5 min at 37°C in the presence of 10 μM sanguinarine, 10 μM berberine or 10 μM chelerythrine, or in the absence of inhibitors, before the addition of 100 μM ATP for a further 4 min. The data are one representative of 13 experiments for chelerythrine and three experiments for sanguinarine and berberine.
Figure 3
Figure 3
Allosteric noncompetitive inhibition of ATP-induced 86Rb+ efflux by chelerythrine. 86Rb+-loaded CLL B-lymphocytes were incubated for 5 min at 37°C in the presence of either 5 or 10 μM chelerythrine or in the absence of chelerythrine before addition of ATP, as indicated for a further 4 min. The data are presented as means ±s.e.m. from three separate experiments.
Figure 4
Figure 4
Chelerythrine inhibits both ATP- and PMA-induced PLD activity. [3H]oleic acid-labelled CLL B-lymphocytes were incubated in KCl medium containing 1 μM BaCl2 in the absence or presence of 10 μM chelerythrine for 15 min prior to the addition of 500 μM ATP or 0.1 μM PMA for a further 15 min at 37°C. The data are presented as means ±s.e.m. from five separate experiments (*P<0.03, **P<0.05, chelerythrine versus control).

References

    1. BOUE-GRABOT E., ARCHAMBAULT V., SEGUELA P. A protein kinase C site highly conserved in P2X subunits controls the desensitization kinetics of P2X2 ATP-gated channels. J. Biol. Chem. 2000;275:10190–10195. - PubMed
    1. CHEN W., RAVI R.G., KERTSEY S.B., DUBYAK G.R., JACOBSON K.A. Functionalized congeners of tyrosine-based P2X7 receptor antagonists: probing multiple sites for linking and dimerization. Bioconjugate Chem. 2002;13:1100–1111. - PMC - PubMed
    1. CHO H., YOUM J.B., EARM Y.E., HO W.K. Inhibition of acetylcholine-activated K+ current by chelerythrine and bisindoylmaleimide I in atrial myocytes from mice. Eur. J. Pharmacol. 2001;424:73–178. - PubMed
    1. COHEN H.G., SEIFEN E.E., STRAUB K.D., TIEFENBACK C., STERMITZ F.R. Structural specificity of NaK-ATPase inhibition by sanguinarine, an isoquinoline benzophenanthridine alkaloid. Biochem. Pharmacol. 1978;27:2555–2558. - PubMed
    1. DUBYAK G.R.Role of P2 receptors in the immune system Purinergic and Pyrimidinergic Signalling II 2001Berlin: Springer Verlag; 323–355.ed. Abbracchio, M.P. & Williams, M. pp

Publication types

MeSH terms

LinkOut - more resources